Skip to content
Parakho

Cipla Ltd

NSE CIPLABSE 500087cipla.com

Q1 FY27, unaudited

Revenue
₹5,077.68 Cr
Profit after tax
₹862.16 Cr

As filed with the exchange, standalone basis.

Board meeting

Cipla Ltd has given BSE notice of a board meeting on 27 Oct 2026 to consider Q2 FY27 results. Notice · Results calendar

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations5,077.68+0.62%18,979.95
Other income242.75−10.45%1,122.65
Total income5,320.43+0.06%20,102.60
Employee benefit expense914.96+11.81%3,350.48
Finance costs5.68−3.40%19.30
Depreciation & amortisation169.39+16.27%658.43
Total expenses4,166.81+16.61%15,222.29
Profit before tax1,153.62−33.85%4,635.94
Tax expense291.46−33.88%1,120.76
Profit after tax862.16−33.84%3,515.18
Total comprehensive income929.44−28.46%3,368.88
Earnings per share
Earnings per share, basic₹10.67₹43.52
Earnings per share, diluted₹10.67₹43.49

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Cipla reported its highest ever Q1 revenue of INR7,119 crores, up 2% year-on-year as reported, with growth adjusted for an accounting presentation change at around 4%. The One India business grew 12% year-on-year with chronic portfolio strength, while North America delivered quarterly revenue of $162 million with the launch of generic Ventolin during the quarter. EBITDA margin excluding other income stood at 16.7%, and management attributed the compression to launch-related investments, one-time inventory charges, and war-related cost impact.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 78 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 28 Sept 2026.